my prescribed supply of Cymbalta ran out at the end of September 2010 – the pharmacy then provided me with three capsules while we awaited a response from the prescribing physician, an ADHD specialist, to whom I’d indicated my plans to stop taking the Cymbalta. in a misguided effort to wean off the Cymbalta while waiting for direction from the doctor, i took the three capsules over the following week. each time Cymbalta is depleted from the system a new round of withdrawal begins. its half-life is reported at twelve to seventeen hours so just missing a day causes bells to sound.
it’s been two months less the start-stop week since I’ve taken Cymbalta. the withdrawal symptoms, or in the terms Lilly use to describe the visit to this oozing, black mire, discontinuation syndrome, continue. lately there have been periods lasting several days where symptoms have remained diminished and the chance that their effects are near depletion raises its hopeful little head. then, just like the fairground game where the idea is to mallet a groundhog that is audacious enough to stick its head out of one the available holes, bam, i get slammed.
besides the bowling-ball head, headaches, inexplicable flashes of rage and depressive bouts i’ve noticed a certain clumsiness; it’s similar but different from the balance / vertigo problem that seems is common among us discontinuation violators; it seems that neural connections to my hands and fingers has been re-routed. the dropping of keys illustrates this well and yesterday i counted no less than five key drops. glad i’m not handling crystal.
there are people on forums who wonder whether some of these symptoms are to remain permanently. two months feel like permanent already and there’s a real issue with becoming too accustomed to these experiences; if Cymbalta has left permanent marks on our central nervous system, it will have an impact on everything we do but, we won’t be able to discern to what degree. what’s normal? has the veterinarian who is about to operate on your dog been taking Cymbalta?
Lilly have generated nearly $10B US since 2004 with Cymbalta, a drug they don’t understand yet work to broaden its usage and distribution. If Lilly’s share price were to drop, on a bad-news sell-off for instance, to $25 from its current $33.9, the value of the company (capitalization) would fall by $10.3B or approximately one-quarter of the company’s value. For those of us living through the results of their greed i.e. selling drugs that do what this stuff does, it would still be grossly unfair.